Dextrose Monohydrate 70% Injection Shortage: Current Availability and Manufacturer Status
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Dextrose Monohydrate 70% Injection, though major manufacturers currently list the medication as available.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Dextrose-Monohydrate.
What's in Shortage
Dextrose Monohydrate 70% Injection (Brand Name: DEXTROSE) is currently listed in a shortage status. This medication is an injection used across several therapeutic categories, including Endocrinology/Metabolism, Gastroenterology, Pediatrics, and other clinical applications.
- Generic Name: Dextrose Monohydrate 70% Injection
- Dosage Form: Injection
- Current Status: Current
- Initial Posting Date: 10/11/2024
- Last Updated: 02/02/2026
Which Manufacturers Are Affected
While the drug remains on the shortage list, the following manufacturers currently report their presentations as available:
- Baxter Healthcare: Available
- Presentation: Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)
- Contact: 888-229-0001
- B. Braun Medical Inc.: Available
- Presentation: Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)
- Contact: 800-227-2862
- Otsuka ICU Medical LLC: Available
- Note: This product is distributed by ICU Medical.
- Presentations: DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07 and NDC 0990-7918-19)
- Contact: 1-866-829-9025 or ProductAvailability@icumed.com
Why There's a Shortage
No specific reason was provided in the source data regarding the cause of this shortage status.
What Patients Should Do
If you or a family member requires Dextrose Monohydrate 70% Injection, please take the following practical steps:
- Consult Your Healthcare Provider: Discuss your treatment plan and any concerns about medication availability with your doctor. They can provide guidance tailored to your specific medical needs.
- Talk to Your Pharmacist: Pharmacists can check current stock levels and may be able to assist in sourcing the medication from different distributors.
- Contact Manufacturers: If you are having difficulty locating the medication, you may use the contact numbers provided above to ask about regional availability.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should always consult with their healthcare provider or professional medical team regarding medication changes or treatment options.
Source
Information attributed to the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.